The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
ZEB 1‐associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat
Open accessAbstract
Therapy resistance is a major clinical problem in cancer medicine and crucial for disease relapse and progression. Therefore, the clinical need to overcome it, particularly for aggressive tumors such as pancreatic cancer, is very high. Aberrant activation of an epithelial-mesenchymal transition (EMT) and an associated cancer stem cell phenotype are considered a major cause of therapy resistance. Particularly, the EMT-activator ZEB1 was shown to confer stemness and resistance. We applied a systematic, stepwise strategy to interfere with ZEB1 function, aiming to overcome drug resistance. This led to the identification of both its target gene miR-203 as a major drug sensitizer and subsequently the class I HDAC inhibitor mocetinostat as epigenetic drug to interfere with ZEB1 function, restore miR-203 expression, repress stemness properties, and induce sensitivity against chemotherapy. Thereby, mocetinostat turned out to be more effective than other HDAC inhibitors, such as SAHA, indicating the relevance of the screening strategy. Our data encourage the application of mechanism-based combinations of selected epigenetic drugs with standard chemotherapy for the rational treatment of aggressive solid tumors, such as pancreatic cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681 · cited 1×
“There are various molecular mechanisms that lead to treatment resistance, and in a general view, many of those have been linked to a stemness-associated survival phenotype (Holohan et al, 2013).”
BackgroundTransitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
Polyak, K., & Weinberg, R. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2620 · Cited by 3,302 · cited 1×
“This is of particular relevance, since EMT and stemness were linked at molecular level, explaining why resistant cancer (stem) cells often acquired an undifferentiated EMT phenotype (Polyak & Weinberg, 2009; Singh & Settleman, 2010; Puisieux et al, 2014).”
BackgroundA decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871 · cited 1×
“Epigenetic drugs are of particular relevance, since they can effectively induce a long-term antitumor memory response, even at low doses without an immediate cytotoxic effect (Baylin & Jones, 2011; Tsai et al, 2012).”
BackgroundEMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545 · cited 1×
“This is of particular relevance, since EMT and stemness were linked at molecular level, explaining why resistant cancer (stem) cells often acquired an undifferentiated EMT phenotype (Polyak & Weinberg, 2009; Singh & Settleman, 2010; Puisieux et al, 2014).”
BackgroundA skin microRNA promotes differentiation by repressing ‘stemness’
Yi, R., Poy, M. N., Stoffel, M., & Fuchs, E. (2008) · Nature · doi:10.1038/nature06642 · Cited by 790
ZEB1: At the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance
Zhang, P., Sun, Y., & Ma, L. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1006048 · Cited by 611 · cited 2×
“Published under the terms of the CC BY 4.0 license EMBO Molecular Medicine Vol 7 | No 6 | 2015 831 well as subsequent downregulation of miR-200, has already been associated with a pro-survival and drug-resistant phenotype (Mongroo & Rustgi, 2010; Zhang et al, 2015).”
BackgroundInfluentialmiR-203 represses ‘stemness’ by repressing ΔNp63
Lena, A. M., Shalom-Feuerstein, R., di Val Cervo, P. R., Aberdam, D., Knight, R. A., Melino, G., & Candi, E. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.69 · Cited by 389 · cited 1×
“…data indicate that besides miR-200, the ZEB1 target miR-203 is an important factor. miR-203 has been described as a stemness-inhibiting microRNA (Lena et al, 2008; Yi et al, 2008; Taube et al, 2013), by suppressing factors such as the self-renewal factor Bmi1 (Shimono et al, 2009; Wellner et…”
Background
Cited by
Nieto, M. A., Huang, R. Y.-J., Jackson, R. A., & Thiery, J. P. (2016) · Cell · doi:10.1016/j.cell.2016.06.028 · Cited by 4,492
HDACs and HDAC Inhibitors in Cancer Development and Therapy
Li, Y., & Seto, E. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026831 · Cited by 1,284
Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment
Phi, L. T. H., Sari, I. N., Yang, Y.-G., Lee, S.-H., Jun, N., Kim, K. S., Lee, Y. K., & Kwon, H. Y. (2018) · Stem Cells International · doi:10.1155/2018/5416923 · Cited by 994
Krebs, A. M., Mitschke, J., Lasierra Losada, M., Schmalhofer, O., Boerries, M., Busch, H., Boettcher, M., Mougiakakos, D., Reichardt, W., Bronsert, P., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3513 · Cited by 975
Self-citationCancer Stem Cells: Basic Concepts and Therapeutic Implications
Nassar, D., & Blanpain, C. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044438 · Cited by 869
Targeting Epithelial–Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer
Du, B., & Shim, J. (2016) · Molecules · doi:10.3390/molecules21070965 · Cited by 807
Dynamic EMT: a multi‐tool for tumor progression
Brabletz, S., Schuhwerk, H., Brabletz, T., & Stemmler, M. P. (2021) · The EMBO Journal · doi:10.15252/embj.2021108647 · Cited by 761
Self-citationThe multi-factorial nature of clinical multidrug resistance in cancer
Assaraf, Y. G., Brozovic, A., Gonçalves, A. C., Jurkovicova, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento-Ribeiro, A. B., Xavier, C. P. R., & Vasconcelos, M. H. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100645 · Cited by 528
Erin, N., Grahovac, J., Brozovic, A., & Efferth, T. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100715 · Cited by 527
Controversies around epithelial–mesenchymal plasticity in cancer metastasis
Williams, E. D., Gao, D., Redfern, A., & Thompson, E. W. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0213-x · Cited by 451
Milazzo, G., Mercatelli, D., Di Muzio, G., Triboli, L., De Rosa, P., Perini, G., & Giorgi, F. M. (2020) · Genes · doi:10.3390/genes11050556 · Cited by 423
Unveiling the mechanisms and challenges of cancer drug resistance
Khan, S. U., Fatima, K., Aisha, S., & Malik, F. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01302-1 · Cited by 417
Taxanes in cancer treatment: Activity, chemoresistance and its overcoming
Mosca, L., Ilari, A., Fazi, F., Assaraf, Y. G., & Colotti, G. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100742 · Cited by 385
EMT‐associated microRNAs and their roles in cancer stemness and drug resistance
Pan, G., Liu, Y., Shang, L., Zhou, F., & Yang, S. (2021) · Cancer Communications · doi:10.1002/cac2.12138 · Cited by 362
Pleiotropic Roles for ZEB1 in Cancer
Caramel, J., Ligier, M., & Puisieux, A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2476 · Cited by 344
EMT transcription factors in cancer development re-evaluated: Beyond EMT and MET
Goossens, S., Vandamme, N., Van Vlierberghe, P., & Berx, G. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.06.006 · Cited by 295
Epithelial-to-Mesenchymal Transition: Epigenetic Reprogramming Driving Cellular Plasticity
Skrypek, N., Goossens, S., De Smedt, E., Vandamme, N., & Berx, G. (2017) · Trends in Genetics · doi:10.1016/j.tig.2017.08.004 · Cited by 271
EMT: Present and future in clinical oncology
Santamaria, P. G., Moreno‐Bueno, G., Portillo, F., & Cano, A. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12091 · Cited by 259
van Staalduinen, J., Baker, D., ten Dijke, P., & van Dam, H. (2018) · Oncogene · doi:10.1038/s41388-018-0378-x · Cited by 158
Improving Taxane-Based Chemotherapy in Castration-Resistant Prostate Cancer
Kroon, J., Kooijman, S., Cho, N.-J., Storm, G., & van der Pluijm, G. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.03.003 · Cited by 64
Understanding the Mechanisms by Which Epigenetic Modifiers Avert Therapy Resistance in Cancer
Quagliano, A., Gopalakrishnapillai, A., & Barwe, S. P. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00992 · Cited by 56
ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism
Peng, D. H., Kundu, S. T., Fradette, J. J., Diao, L., Tong, P., Byers, L. A., Wang, J., Canales, J. R., Villalobos, P. A., Mino, B., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaq1238 · Cited by 53
“Previous studies have shown that the class I HDAC inhibitor mocetinostat reverts the EMT phenotype through restoring the expression of epithelial microRNAs, including the miR-200 family (51).”
Engaging plasticity: Differentiation therapy in solid tumors
Bar-Hai, N., & Ishay-Ronen, D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.944773 · Cited by 35
Byeon, H. K., Na, H. J., Yang, Y. J., Ko, S., Yoon, S. O., Ku, M., Yang, J., Kim, J. W., Ban, M. J., Kim, J.-H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.13480 · Cited by 29
Metadata
- Authors
- Meidhof, S., Brabletz, S., Lehmann, W., Preca, B., Mock, K., Ruh, M., Schüler, J., Berthold, M., Weber, A., Burk, U., Lübbert, M., Puhr, M., Culig, Z., Wellner, U., Keck, T., Bronsert, P., Küsters, S., Hopt, U. T., Stemmler, M. P., & Brabletz, T.
- Venue
- EMBO Molecular Medicine
- Published
- 2015-04-14
- Volume
- 7
- Issue
- 6
- Pages
- 831-847
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2103771206
- Cited by
- 229
- References
- 7
- FWCI
- 10.79
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.